Trial document




drksid header

  DRKS00015218

Trial Description

start of 1:1-Block title

Title

RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus
A phase II trial to evaluate safety and efficacy of adding durvalumab (MEDI4736) to standard neoadjuvant radiochemotherapy and of adjuvant durvalumab +/- tremelimumab in locally advanced esophageal adenocarcinoma and to evaluate biomarkers predictive for response to immune checkpoint inhibition

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

RICE

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

A phase II trial to evaluate safety and efficacy of adding durvalumab (MEDI4736) to standard neoadjuvant radiochemotherapy and of adjuvant
durvalumab +/- tremelimumab in locally advanced esophageal adenocarcinoma and to evaluate biomarkers predictive for response to immune checkpoint inhibition.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

A phase II trial to evaluate safety and efficacy of adding durvalumab (MEDI4736) to standard neoadjuvant radiochemotherapy and of adjuvant durvalumab +/- tremelimumab in locally advanced esophageal adenocarcinoma and to evaluate biomarkers predictive for response to immune checkpoint inhibition.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00015218
  •   2019/09/05
  •   [---]*
  •   yes
  •   Approved
  •   19-1150_1-AMG-ff, Ethik-Kommission der Medizinischen Fakultät der Universität zu Köln
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   2018-003048-22 
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   C15 -  Malignant neoplasm of oesophagus
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   1. Imfinzi (Durvalumab) 1500mg i.v. at day 1 and day 29, time: 60 Min
    Paclitaxel 50mg/m² at day 1; 8; 15; 22; 29, time: 60 Min
    Carboplation AUC 2 at day 1; 8; 15; 22; 29, time: 60 Min
    radiationtherapy at 5 days with 1,8Gy/each up to 41,4Gy in total (23 days in total)

    2. Imfinzi (Durvalumab), 1500mg i.v., every 4 weeks for 12 months total
  •   1. Imfinzi (Durvalumab) 1500mg i.v. at day 1 and day 29, time: 60 Min
    Paclitaxel 50mg/m² at day 1; 8; 15; 22; 29, time: 60 Min
    Carboplation AUC 2 at day 1; 8; 15; 22; 29, time: 60 Min
    radiationtherapy at 5 days with 1,8Gy/each up to 41,4Gy in total (23 days in total)

    2. Imfinzi (Durvalumab), 1500mg i.v., every 4 weeks for 12 months total + tremelimumab i.v. every 4 weeks for 4 months total
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Open (masking not used)
  •   [---]*
  •   Active control (effective treament of control group)
  •   Treatment
  •   Parallel
  •   II
  •   No
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

The primary endpoint for efficacy is the pathological complete response rate (pCR, ypT0, ypN0, M0), measured by standardized pathological examination of the resection specimens.
The primary endpoint for safety is incidence, severity and grading of treatment emergent AEs and SAEs.
The resection specimens will be taken during each patient's surgery.

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

1. To determine the Best Objective Response (BOR) as defined by RECIST 1.1 and iRECIST criteria after neoadjuvant treatment
2. To determine Progression free survival (PFS), Disease free survival (DFS) and Overall Survival (OS) in durvalumab vs. durvalumab + tremelimumab adjuvant treatment
3. To assess the subject’s esophageal-cancer-related quality of life using the Functional Assessment of Cancer Therapy-Esophageal (FACT-E) questionnaire

The results of the secondary endpoints will be determined after last patients last visit (LPLV).

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • University Medical Center 
  • University Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Actual
  •   2019/09/30
  •   56
  •   Multicenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

1. Study participants must have signed and dated an IRB/IEC approved written informed consent form
2. Study participants must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests and other requirements of the study.
3. Histologically confirmed, resectable adenocarcinoma of the esophagus (uT3, cNx, cM0), with the following specifications:
• Medical and technical operability
• No preceding cytotoxic or targeted therapy
• No prior partial or complete tumor resection
4. Male or female patients ≥ 18 years of age at time of consent
5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
6. Study participants must be willing to undergo at least 2 biopsies (baseline, after neoadjuvant treatment)
7. Life expectancy of ≥ 12 months
8. Body weight ≥ 30kg
9. Adequate normal blood and marrow function as defined below
• WBC ≥ 1500/µL
• Neutrophils ≥ 1000/μL
• Platelets ≥ 75 x103/μL
• Hemoglobin > 9.0 g/dL
• Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 40 mL/min (Cockcroft-Gault) measured creatinine clearance(CL) > 40 mL/min or calculated creatinine clearance CL > 40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance
• AST/ALT (SGOT/SGPT) ≤ 2,5x ULN
• Total Bilirubin ≤ 1.5 x ULN (except study participants with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL)
10. Reproductive Status
• Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception and must agree to use adequate method to avoid pregnancy for 7 month after the last dose of study drug.
• Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of ß-HCG) within one until two weeks prior to the start of durvalumab at time of neoadjuvant treatment and after surgery before starting adjuvant treatment.
• Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men receiving durvalumab and who are sexually active with WOCBP must be willing to adhere to contraception for a period of 7 month post treatment completion.
• Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:
• Women < 50 years of age would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).
• Women ≥ 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses > 1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

1. Study participants with squamous cell carcinoma of the esophagus
2. Prior treatment with chemotherapy, targeted therapy or radiotherapy for treatment of advanced disease
3. Patients are excluded if they are not resectable because of tumor infiltrating any other organs (cM1), except the stomach, or if they are not resectable in case of other serious or uncontrolled medical disease.
4. Patients with tumor stadium less than uT3 or confirmed metastatic diseases
5. Any other serious or uncontrolled medical disorder, active infections, physical exam findings, laboratory finding, altered mental status, or psychiatric condition that, in the opinion of the investigator, would limit a study participant’s ability to comply with the study requirements, substantially increase risk to the study participant, or impact the interpretability or study results
6. Presence or history of any other primary malignancy other than adenocarcinoma of the esophagus within 5 years prior to enrolment into the trial, except for adequately treated basal or squamous cell carcinoma of the skin or any adequately treated in situ carcinoma.
7. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion:
• Patients with vitiligo or alopecia
• Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement
• Any chronic skin condition that does not require systemic therapy
• Patients without active disease in the last 5 years may be included but only after consultation with the study physician
• Patients with celiac disease controlled by diet alone.
• Patients with a condition requiring systemic treatment with either corticosteroids (> 10mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first dose of study drug administration. Inhaled or topical steroids and adrenal replacement steroid doses > 10mg daily prednisone equivalent are permitted in the absence of active autoimmune disease.
8. History of active primary immunodeficiency
9. History of any allogenic organ transplantation with currently intake of immune suppressive treatment
10. Positive test for hepatitis B or hepatitis C or E indicating acute or chronic infection
11. Patients are excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
12. History of another primary malignancy except for
• Malignancy treated with curative intent and with no known active disease ≥ 5 years before the first dose of IP and of low potential risk for recurrence
• Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
• Adequately treated carcinoma in situ without evidence of disease
13. Patients with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity.
14. Patients has known current symptomatic congestive heart failure (NYHA III and IV), unstable angina pectoris, or cardiac arrhythmia
15. Prisoners or study participants who are involuntarily incarcerated
16. Allergies and Adverse Drug Reaction
a. History of allergy to study drug components
b. History of severe hypersensitivity reaction to any monoclonal antibody
17. Current treatment within another therapeutic clinical trial with experimental and not approved drugs and treatment combinations.
18. Pregnant or breastfeeding females

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Universität zu Köln
    • Albertus-Magnus-Platz
    • 50923  Köln
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Universitätsklinikum Köln Klinik I für Innere Medizin
    • Mr.  Priv.-Doz. Dr. med.  Thomas  Zander 
    • Kerpener Straße 62
    • 50937  Köln
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Universitätsklinikum Köln Studienzentrum der Klinik I für Innere Medizin
    • Ms.  Katrin  von Schimmelmann 
    • Kerpener Str 62
    • 50937  Köln
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • AstraZenca GmbH
    • Tinsdaler Weg 183
    • 22880  Wedel
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.